Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | GHSR | Q92847 | 12/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13943090 | 1.00 | CHRNB4 (0.42) | CHRNB4CHRNA3GHSRCHRNB2CHRNA4 | |
| SCHEMBL3646957 | 0.86 | CHRNB2 (0.42) | GHSRCHRNB2CHRNA4 | |
| SCHEMBL3646824 | 0.85 | CHRNB4 (0.44) | CHRNB4CHRNA3GHSR | |
| SCHEMBL13943096 | 0.85 | CHRNB4 (0.44) | CHRNB4CHRNA3GHSR | |
| SCHEMBL13943580 | 0.82 | GHSR (0.46) | CHRNB4CHRNA3GHSR | |
| SCHEMBL3651845 | 0.82 | GHSR (0.46) | CHRNB4CHRNA3GHSR | |
| SCHEMBL3646815 | 0.79 | GHSR (0.48) | GHSRCHRNB2CHRNA4 | |
| SCHEMBL13943098 | 0.79 | GHSR (0.48) | GHSRCHRNB2CHRNA4 | |
| SCHEMBL3643849 | 0.79 | GHSR (0.48) | GHSRCHRNB2CHRNA4 | |
| SCHEMBL3762400 | 0.73 | GHSR (0.44) | CHRNB4CHRNA3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183216-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| WO-2009016048-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | claimed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2183216-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016048-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | CHRNB4 423/4885CHRNA3 251/4885GHSR 72/4885 |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | CHRNB4 423/4885CHRNA3 251/4885GHSR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.